maviret
abbvie deutschland gmbh co. kg - glecaprevir, pibrentasvir - hepatitis c kronisk - antivirale midler til systemisk anvendelse - maviret is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults and children aged 3 years and older. maviret coated granules is indicated for the treatment of chronic hepatitis c virus (hcv) infection in children 3 years and older.
engerix 10 mikrogram/0,5 ml 20 mikrogram/ml injektionsvæske, suspension, fyldt injektionssprøjte
orifarm a/s - hepatitis b virus overfladeantigen (rdna) - injektionsvæske, suspension, fyldt injektionssprøjte - 20 mikrogram/ml
engerix b 20 mikrogram/ml injektionsvæske, suspension, fyldt injektionssprøjte
orifarm a/s - hepatitis b virus overfladeantigen (rdna) - injektionsvæske, suspension, fyldt injektionssprøjte - 20 mikrogram/ml
engerix-b 10 mikrogram/0,5 ml 20 mikrogram/ml injektionsvæske, suspension
glaxosmithkline pharma a/s - hepatitis b virus overfladeantigen (rdna) - injektionsvæske, suspension - 20 mikrogram/ml
vaqta 50 e./ml injektionsvæske, suspension
merck sharp & dohme b.v. - hepatitis a virus, stamme cr 326f (inaktiveret) - injektionsvæske, suspension - 50 e./ml
vosevi
gilead sciences ireland uc - sofosbuvir, velpatasvir, voxilaprevi - hepatitis c kronisk - antivirale midler til systemisk anvendelse - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients aged 12 years and older and weighing at least 30 kg. (se afsnit 4. 2, 4. 4 og 5.
hepcludex
gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - antivirale midler til systemisk anvendelse - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.
avaxim junior injektionsvæske, suspension, fyldt injektionssprøjte
sanofi pasteur europe - hepatitis a virus, stamme gbm (inaktiveret) - injektionsvæske, suspension, fyldt injektionssprøjte
uman big 180 ie/ml injektionsvæske, opløsning
orifarm a/s - hepatitis b immunglobulin, humant - injektionsvæske, opløsning - 180 ie/ml
imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastiske midler - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.